← Back to Search

Enzyme Inhibitor

Eflornithine + Sulindac for Colorectal Cancer Prevention (PACES Trial)

Phase 3

Recruiting

Led By Jason A. Zell, D.O., MPH

Research Sponsored by Southwest Oncology Group

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Post-operative colonoscopy and CT scans of chest, abdomen & pelvis showing no evidence of disease

Must not have cardiovascular risk factors including unstable angina, history of myocardial infarction, or cerebrovascular accident, coronary artery bypass surgery, or NY Heart Assoc Class III or IV heart failure.

Must not have

History of colon resection > 40 cm

Mid-low rectal cancer

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 8 years

Awards & highlights

Summary

This trial will test a combination of drugs to see if they are effective in reducing the chance of cancer recurrence or developing new cancers.

Who is the study for?

This trial is for adults who've had Stage 0-III colon or rectal cancer and completed surgery a year ago, with no current evidence of disease. They must have finished chemo and radiation at least 30 days prior, be able to swallow pills, not take certain drugs regularly (like NSAIDs), and have stable vital signs. Pregnant women or those with high cardiovascular risks are excluded.

What is being tested?

The study tests if eflornithine combined with sulindac can prevent the return of adenomas or colorectal cancers in patients previously treated for these conditions. Participants will receive either both drugs, one drug plus a placebo, or double placebos over three years.

What are the potential side effects?

Possible side effects include digestive issues like ulcers (for those taking sulindac), hearing loss (eflornithine has been linked to this in some cases), allergic reactions if sensitive to NSAIDs, and general medication-related risks such as liver function changes.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My recent scans after surgery show no signs of cancer.

Select...

I do not have serious heart conditions or recent major heart events.

Select...

I do not have uncontrolled high cholesterol or blood pressure.

Select...

I am not regularly taking steroids, NSAIDs more than 10 days a month, or blood thinners.

Select...

My recent scans after surgery show no signs of cancer.

Select...

I do not have serious heart problems or recent major heart events.

Select...

I don't have uncontrolled high cholesterol or blood pressure.

Select...

I can take pills by mouth.

Select...

I am 18 or older and mostly active without needing care.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have had surgery to remove more than 40 cm of my colon.

Select...

My cancer is in the lower part of my rectum.

Select...

My cancer has returned or spread to other parts of my body.

Select...

I have a high risk of heart problems and my high blood pressure is not under control.

Select...

I am scheduled for more chemotherapy or radiation therapy.

Select...

I have had a stomach or upper small intestine ulcer in the past year.

Select...

I have a family history of specific colon conditions or have inflammatory bowel disease.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 8 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 8 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 8 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Event rate, defined as rate of high-risk adenoma or second primary colorectal cancer (CRC)

Secondary study objectives

Adenomas >= 1 cm

Adenoma

Baseline meat consumption

+12 more

Trial Design

4Treatment groups

Experimental Treatment

Placebo Group

Group I: Eflornithine plus sulindacExperimental Treatment1 Intervention

Eflornithine two 250 mg tablets PO daily for 3 years. Sulindac one 150 mg tablet PO daily for 3 years.

Group II: Eflornithine placebo & sulindacExperimental Treatment1 Intervention

Eflornithine placebo 2 tablets PO daily for 3 years. Sulindac one 150 mg tablet PO daily for 3 years.

Group III: Eflornithine & sulindac placeboExperimental Treatment1 Intervention

Eflornithine two 250 mg tablets PO daily for 3 years. Sulindac placebo one tablet PO daily for 3 years.

Group IV: eflornithine placebo & sulindac placeboPlacebo Group1 Intervention

Eflornithine placebo 2 tablets, PO, daily for 3 years. Sulindac placebo, 1 tablet, PO, daily for 3 years.

0 / 16Eligibility criteria met

Find a Location

Who is running the clinical trial?

Southwest Oncology GroupLead Sponsor

388 Previous Clinical Trials

259,921 Total Patients Enrolled

National Cancer Institute (NCI)NIH

13,748 Previous Clinical Trials

40,958,061 Total Patients Enrolled

Cancer Prevention Pharmaceuticals, Inc.Industry Sponsor

7 Previous Clinical Trials

442 Total Patients Enrolled

Media Library

Eflornithine (Enzyme Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT01349881 — Phase 3

Colorectal Cancer Research Study Groups: Eflornithine plus sulindac, Eflornithine & sulindac placebo, Eflornithine placebo & sulindac, eflornithine placebo & sulindac placebo

Colorectal Cancer Clinical Trial 2023: Eflornithine Highlights & Side Effects. Trial Name: NCT01349881 — Phase 3

Eflornithine (Enzyme Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01349881 — Phase 3

Colorectal Cancer Patient Testimony for trial: Trial Name: NCT01349881 — Phase 3

~225 spots leftby Feb 2027

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.